PP
MCRB icon

PagnatoKarp Partners’s Seres Therapeutics MCRB Stock Holding History

PagnatoKarp Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-508
Closed -$36K – 86
2020
Q1 		$36K Buy
+508
New +$34.1K 0.01% 166

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PagnatoKarp Partners's MCRB Position: Q2 2020 in Review

PagnatoKarp Partners sold out of Seres Therapeutics (MCRB) in Q2 2020, closing a stake of 508 shares — an estimated $36K sold.

PagnatoKarp Partners first reported a position in MCRB in Q1 2020 and held it in 1 quarter. The position peaked at $36K in Q1 2020. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2020.

  • PagnatoKarp Partners reported no remaining Seres Therapeutics position as of Q2 2020 after selling out during the quarter.
  • PagnatoKarp Partners sold 508 Seres Therapeutics shares in Q2 2020, an estimated $36K.
  • PagnatoKarp Partners first reported a position in Seres Therapeutics in Q1 2020 and held it in 1 quarter.
  • PagnatoKarp Partners's Seres Therapeutics position peaked at $36K in Q1 2020.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.